article thumbnail

BREAKING: Breast cancer drug licensed as preventative measure

Outsourcing Pharma

A breast cancer drug that has been used for many years to treat the disease, has been licensed today (November 7) as a preventative measure.

Licensing 111
article thumbnail

Sosei to regain rights to IBD drug after GSK discontinues programme

Pharmaceutical Technology

The Sosei Heptares oral IBD drug was first licensed to GSK in 2020 and is currently in Phase I clinical development.

Licensing 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche licenses drug to target cancer DNA damage response

Outsourcing Pharma

Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQâs lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.

DNA 91
article thumbnail

Ablaze Pharmaceuticals to develop drug candidate for liver cancer

Pharmaceutical Technology

Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China.

article thumbnail

Acrivon Nets $100 Million and Licenses Cast-Off Lilly Oncology Drug

BioSpace

Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.

Licensing 101
article thumbnail

Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate

Pharmaceutical Technology

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). We look forward to working with CSPC to advance clinical development of this asset and realise its full potential.”

Antibody 130
article thumbnail

ImmunoForge expands agreement with Duke University for drug development

Pharmaceutical Technology

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.